Embecta (EMBC) Net Income towards Common Stockholders (2020 - 2026)
Embecta (EMBC) reported Net Income towards Common Stockholders of -$4.1 million for Q1 2026, down 117.45% on a YoY basis from $23.5 million in Q1 2025, and down 109.3% sequentially from $44.1 million in Q4 2025.
Embecta (EMBC) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Embecta (EMBC) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$4.1 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 117.45% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at $111.9 million (up 111.93% YoY), and the FY2025 full-year result was $95.4 million, up 21.84% from the prior year.
- Net Income towards Common Stockholders declined to -$4.1 million in Q1 2026, from $44.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $79.6 million in Q1 2022 to a low of -$17.2 million in Q3 2022.
- A 5-year average of $25.6 million and a median of $21.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders slumped 117.75% in 2022 and soared 209.52% in 2025, its largest moves.
- Tracing EMBC's Net Income towards Common Stockholders over 5 years: stood at $35.2 million in 2022, then slumped by 42.9% to $20.1 million in 2023, then retreated by 27.36% to $14.6 million in 2024, then surged by 202.05% to $44.1 million in 2025, then sank by 109.3% to -$4.1 million in 2026.
- Business Quant data shows EMBC's Net Income towards Common Stockholders at -$4.1 million in Q1 2026, $44.1 million in Q4 2025, and $26.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 124.80 Bn | 119.58 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 44.47 Bn | 43.65 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Alcon | 33.17 Bn | 31.51 Bn | 1.53 Bn | 22.13 Bn |
| 4 | Medline | 32.67 Bn | 30.44 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 29.06 Bn | 27.40 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.50 Bn | 23.06 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 13.91 Bn | 13.35 Bn | 1.10 Bn | 13.00 Mn |
| 8 | Cooper Companies | 13.82 Bn | 13.68 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Align Technology | 12.13 Bn | 11.07 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Embecta | 201.02 Mn | 7.62 Mn | 127.80 Mn | -4.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.10 Mn |
| Dec 31, 2025 | 44.10 Mn |
| Sep 30, 2025 | 26.40 Mn |
| Jun 30, 2025 | 45.50 Mn |
| Mar 31, 2025 | 23.50 Mn |
| Sep 30, 2024 | 14.60 Mn |
| Jun 30, 2024 | 14.70 Mn |
| Mar 31, 2024 | 28.90 Mn |
| Dec 31, 2023 | 20.10 Mn |
| Sep 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 15.20 Mn |
| Mar 31, 2023 | 14.00 Mn |
| Dec 31, 2022 | 35.20 Mn |
| Sep 30, 2022 | -17.20 Mn |
| Jun 30, 2022 | 62.40 Mn |
| Mar 31, 2022 | 79.60 Mn |
| Dec 31, 2021 | 98.80 Mn |
| Sep 30, 2021 | 96.90 Mn |
| Jun 30, 2021 | 104.70 Mn |
| Mar 31, 2021 | 107.90 Mn |